Adjuvant Therapy for Hepatocellular Carcinoma

Patients with hepatocellular carcinoma (HCC) with preoperative vascular invasion, poorly differentiated histology, large or multifocal tumors, and elevated α-fetoprotein levels have traditionally had a poor prognosis. Systemic adjuvant therapies after liver resection for tumors with high-risk features are not well studied. Given the advancement in tyrosine kinase inhibitor and immunotherapy for advanced HCCs, several phase 3 randomized clinical trials (RCTs) are investigating these agents in the adjuvant setting. The first of these, the STORM trial, which evaluated sorafenib for HCC after resection or ablation, did not show a benefit for its use as adjuvant therapy.
Source: JAMA Surgery - Category: Sports Medicine Source Type: research